PedAM
Pediatric Disease Annotations & Medicines
| Disease | irritable bowel syndrome |
| Phenotype | |constipation |
| Sentences | 59 |
| PubMedID- 23162373 | Burden of constipation-predominant irritable bowel syndrome (ibs-c) in france, italy, and the united kingdom. |
| PubMedID- 22963061 | Lubiprostone is effective for the treatment of constipation-predominant irritable bowel syndrome, and alosetron (restrictions for use apply in the united states) and tegaserod (available only for emergency use in the united states) are approved for patients with severe symptoms in whom conventional therapy has been ineffective. |
| PubMedID- 25781368 | Introduction: the irritable bowel syndrome with constipation (ibs-c) and chronic idiopathic constipation (cic) are associated with substantial symptom and disease burden. |
| PubMedID- 26533548 | The burden of moderate-to-severe irritable bowel syndrome with constipation (ibs-c) in france: a comparison with the european results from the ibis-c observational study. |
| PubMedID- 24812563 | The study of ardatskaia on 30 patients having irritable bowel syndrome with predominance of constipation showed that normoflorin therapy had normalized the intestinal motor activity through changes in microbial flora of the intestines [12]. |
| PubMedID- 22830234 | Objective: to evaluate the clinical effectiveness of biocomplexes "normoflorin l, b" in the treatment of functional bowel disease with constipation syndrome. |
| PubMedID- 22847198 | Material/methods: thirty patients with a diagnosis of constipation-predominant irritable bowel syndrome and 30 healthy volunteers were included in the study. |
| PubMedID- 25653859 | Background: optimal clinical trial endpoints for irritable bowel syndrome with constipation (ibs-c) are uncertain. |
| PubMedID- 20200325 | Objectives: tegaserod, a partial 5-ht(4) agonist previously approved for treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation, was suspended from us marketing in 2007, based on pooled clinical trial results which contained a signal suggesting increased risk of cardiovascular ischemic events (cvies). |
Page: 1 2